Director of MIT’s cancer research center to step down

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.

Erica Carbajal –
Monday, October 26th, 2020
Print|Email.

More posts on oncology: Viewpoint: Online oncology forums can feed verification biasWomen with inflammatory breast cancer now living longer, however racial variations stay, study says4 recent cancer care collaborations.

Tyler Jacks, PhD, will step down from the Koch Institute for Integrative Cancer Research at MIT in Cambridge, Mass. after functioning as director for over 19 years..

By partnering with associates, Dr. Jacks established several specialty cancer centers and programs, consisting of the Ludwig Center for Molecular Oncology, the Marble Center for Cancer Nanomedicine and the MIT Center for Precision Cancer Medicine. Dr. Jacks has raised about $375 million to support developments in cancer research study and specialized centers throughout his career..

Dr. Jacks will continue cancer genetics research study, mentor at the Koch Institute and representing the Bridge Project, a collaboration between the Koch Institute and Boston-based Dana-Farber/Harvard Cancer Center that intends to resolve difficult cancer research study problems..

Dr. Jacks oversaw efforts to advance collaborative cancer research study with the transformation of the MIT Cancer for Center Research into the Koch Institute in 2007 by combining life scientists and engineers to better understand the biology of cancer..

Phillip Sharp, PhD, a teacher at the institute, will head a search committee for Jacks follower as director of the Koch Institute..

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.

As a pioneer in the usage of gene-targeting to engineer thorough human cancer models, Dr. Jacks mouse models are utilized by researchers across the world. His current mouse design research is expected to determine unique immune based therapies for human cancer..